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Abstract
Background: This study was conducted to elucidate if nitric oxide is released by the porcine
jejunal mucosa upon selective stimulation of AT2 receptors and the possible involvement of iNOS,
and to investigate the presence of jejunal AT1 and AT2 receptors. Young landrace pigs were
anaesthetized with ketamine and α-chloralose. Jejunal luminal NO output was assessed by
intraluminal tonometry and analysed by chemiluminescense. Western blot analysis quantified
mucosal iNOS and detected AT1 and AT2 receptor protein expression. AT1 and AT2 receptor
RNA expression was detected by rtPCR.
Results: Baseline luminal NO output correlated significantly to baseline mucosal iNOS-protein
content. In animals treated with the AT2-receptor agonist CGP42112A (n = 11) luminal NO output
increased significantly (at 0.1 micrograms kg-1 min-1 and 1.0 micrograms kg-1 min-1), but not in
animals simultaneously treated with the AT2-receptor antagonist PD123319 (bolus 0.3 mgkg-1,
infusion 0.03 mg kg-1 h-1) (n = 7). No differences in iNOS protein expression were found between
groups or before/after the administration of drugs. Western blot and rtPCR recognised expression
of the AT1 and AT2 receptors in jejunal tissue.
Conclusion: The results suggest that activation of AT2 receptors increases jejunal luminal NO
output. This response was not due to an increase in the expression of the iNOS protein in the
mucosa.
Background
The overall function of the renin-angiotensin system
(RAS) and its key mediator angiotensin II (Ang II) is to
maintain extracellular fluid volume and the electrolyte
homeostasis, as well as to regulate vascular tone and
blood pressure. Traditionally, the RAS is regarded as an
endocrine system, but components of the RAS can be
found in several tissues eg kidney, brain, adrenals and the
reproductive organs, suggesting paracrine/autocrine func-
tions [1,2]. Most of the effects of Ang II, including cardio-
vascular, are mediated by activation of angiotensin II
receptor type 1 (AT1 receptor)[2]. Efforts have recently
been made to correlate biological functions to the angi-
otensin II receptor type 2 (AT2 receptor). Involvement in
cell differentiation and inhibition of cell proliferation,
particularly in fetal development, has been demonstrated
[2]. In the adult organism the AT2 receptor has been
shown to be present in eg ovaries, adrenal medulla and
pancreas. It has also been identified in the gut [3–5] where
it is suggested to influence jejunal sodium and water
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absorption and secretion, probably involving the release
of nitric oxide (NO) and the generation of cyclic guanos-
ine 3, 5-monophosphate (cGMP) [6,7]. Johansson et al
[4] demonstrated that rat duodenal mucosal bicarbonate
secretion increased upon administration of the AT2-recep-
tor agonist CGP42112A (0.1 µg kg-1 min-1). Furthermore,
rat duodenal mucosal bicarbonate secretion has been
shown to be regulated partly by NO [8].
The present study aimed to investigate if nitric oxide is re-
leased by the porcine jejunal mucosa upon the pharmaco-
logical activation (CGP42112A) of intestinal AT2
receptors and if a dynamic iNOS-protein expression is in-
volved. Additionally, the study aimed to investigate the
existence and expression of the AT1 and AT2 receptors in
the porcine jejunum.
Results
NO output and iNOS expression
Baseline NO output varied considerably between individ-
uals; range: 46 to 1138 ppb, but exhibited a positive cor-
relation to the baseline mucosal iNOS content (Rho 0.65,
p < 0.01). No significant differences in NO output were
detected between groups at baseline. Luminal NO output
increased in all animals treated with only CGP42112A
(group B) at the doses 0.1 µg kg-1 min-1 and1.0 µg kg-1
min-1, compared to controls (group A) and to animals
treated with PD123319 and CGP42112A simultaneously
(group C) (Figure 1). Acute administration of PD123319
did not alter the baseline NO levels, as tested in separate
experiments (n = 5, data not shown).
Western blot analysis did not detect any significant differ-
ences of iNOS expression between groups at baseline. The
iNOS protein expression did not change significantly in
any group and there were no significant differences be-
tween groups (ratio post-/pre-treatment) (Figure 2).
AT1 and AT2 receptor expression
Western blot using antibodies specific for AT1 and AT2 re-
ceptor proteins recognised bands of the expected molecu-
lar weight 41 kDa and 44 kDa, respectively, in all samples
(n = 11) (Figure 3).
The rtPCR using specific primers for AT1, AT2 receptor
and GAPDH, respectively, recognised expression of RNA
in all samples (n = 11) (Figure 4). The median ratio AT1/
Figure 1
NO output recordings, presented as values relative to base-
line, during infusion of A: saline (150 mM NaCl) (n = 5), B: 
CGP 42112A at increasing infusion rates (0.01 µg kg -1 min-1, 
0.1 µg kg -1 min-1,1.0 µg kg -1 min-1) each lasting 45 min (n = 
11), C: CGP 42112A (as in B) in the presence of PD123319 
(0.3 mg kg-1 iv bolus and 0.03 mg kg-1 h-1 iv infusion adminis-
tration initiated at baseline) (n = 7). A p-value < 0.05 was 
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C; PD123319 +CGP 42112A
0.1 1.0 Figure 2
The ratio post- to pre-treatment iNOS protein expression 
(optical density). iNOS expression did not change signifi-
cantly in any group and the change did not differ significantly 
between the groups: A: saline (150 mM NaCl) (n = 6), B: 
CGP 42112A at increasing infusion rates (0.01 µg kg-1 min-1, 
0.1 µg kg-1 min-1,1.0 µg kg-1 min-1 iv) (n = 6), C: CGP 42112A 
(as in B) in the presence of PD123319 (0.3 mg kg-1 iv bolus 
and 0.03 mg kg-1h-1 iv infusion administration initiated at 
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GAPDH and AT2/GAPDH were 0.429 (range 0.167–
2.117; n = 11) and 0.645 (range 0.429–1.556; n = 11),
respectively.
Hemodynamics
The hemodynamic variables (portal venous flow, cardiac
output, heart rate and mean arterial pressure) did not dif-
fer between groups at baseline and were stable throughout
the protocol, except for a slight but significant decrease in
mean arterial pressure in group C.
Discussion
The present study demonstrates that intravenous infusion
of the AT2 receptor ligand CGP42112A [13,14] stimulates
jejunal luminal NO output. The effect was absent in pres-
ence of the AT2 receptor blocker PD123319 giving strong
support to the assumption that AT2 receptors initiate in-
testinal luminal NO formation. Jejunal nitric oxide forma-
tion was assessed using intraluminal tonometry, a
method previously described for intestinal use by Snygg et
al [15]. By definition the tonometric approach allows de-
termination of NO levels in the close vicinity to the gas-
equilibrating balloon. The NO levels obtained by this
technique therefore reflect mainly NO formation in the
luminal compartment and the mucosa located close to the
luminal compartment. Furthermore, immunohistochem-
istry has revealed that the source for NO as assessed by a
luminal tonometer is iNOS situated in the surface epithe-
lial layer of the mucosa [15]. Nitric oxide may also be syn-
thetized by endothelial NOS (eNOS) and neuronal NOS
Figure 3
Western blot experiments using specific antibodies to AT1 and AT2 receptors, respectively. Staining for AT1 receptor detect 
a single band at the size 41 kDa in all individuals (n = 11) and the PC12 cell lysate serving as a positive control. Staining for AT2 
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(nNOS). These NOS isoforms are situated in deeper layers
of the intestinal wall [15] and it is unlikely that NO pro-
duced in the submucosa can reach the luminal compart-
ment due to the rapid elimination by hemoglobin in such
a highly perfused tissue. Our study confirms that iNOS is
present in the pig jejunal mucosal epithelium and demon-
strates a significant positive correlation between enzyme
expression and NO output during basal conditions. The
results also suggest that baseline NO output is determined
by the amount of available synthase. This observation
gives additional support to the view that luminal tonom-
etry reflects mucosal epithelial NO synthesis. It may also
explain why the measured luminal output of NO by the
pig jejunal mucosa varies between individuals. The factors
regulating intestinal epithelial iNOS expression is not
completely known. Luminal microbial factors may be in-
volved [16] as well as nutrient and digestive factors. The
present approach using systemic drug administration
makes it impossible to evaluate if the AT2-receptor medi-
ated point of action is situated in the mesenteric area or
elsewhere. However, local actions in the gut are expected
as the AT2 receptor is present in the intestine of the rat and
particularly in the mucosa [3,4]. Our current data sup-
ports this hypothesis as both RNA and protein expression
of the AT2 receptor were detected in the jejunal wall of the
pig. In the literature AT2-receptor mediated actions on
vascular tone have been reported in terms of vasodilation
and decrease of arterial pressure and particularly so during
pathological conditions with increased AT2 receptor ex-
pression [2,17] eg in hypertensive states [18]. It was thus
not surprising that an effect on MAP was not obtained
upon infusion of the AT2 receptor agonist in the present
study on healthy young pigs.
Several studies performed in vivo have demonstrated that
CGP42112A is an agonist and that PD123319 is an
Figure 4
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antagonist at the AT2 receptor [4,6,7,13,14]. The present
study shows that CGP42112A stimulates jejunal mucosal
NO output. The sensitivity to PD123319 of this response
speaks in favour of a selective action via the AT2 receptor
in turn activating NO synthesis. AT2-receptor mediated
NO dependent functional alterations have been reported
also in the gastrointestinal tract [6] but direct measure-
ments of NO synthesis in response to AT2-receptor activa-
tion in the intestine have not until now been reported.
AngII has previously been shown to induce eNOS expres-
sion in the kidney [19] but the receptor involved was not
evaluated. Furthermore, it has been reported that AngII
can activate NFκB [20] and particularily via the AT2 recep-
tor [21,22]. This transcription factor regulates the expres-
sion of several inflammatory mediators and among these
iNOS [23,24]. It was found in the present study that epi-
thelial iNOS expression did not increase in mucosal spec-
imens from the CGP42112A-treated animals. These
results indicate that AT2-receptor stimulation does not
activate the intestinal iNOS enzyme expression, at least
not in the short term perspective. Taken together, the
present study shows that selective AT2 receptor stimula-
tion activates mucosal NO output. This may involve facil-
itation of the L-Arginine/NO pathway on the enzymatic
level. The functional significance of increased mucosal
NO formation in response to AT2-receptor stimulation re-
mains to be investigated. Interestingly, RAS plays a role as
a regulator of various inflammatory conditions including
NO synthesis [25]. Intestinal epithelial NO, on the other
hand, is proposed to be a key mediator of intestinal mu-
cosal barrier functions and of host defence mechanisms
against potentially noxious luminal agents [26]. It can
thus be speculated that the present study reveals a previ-
ously unknown regulatory link between the RAS and the
barrier properties of the gastrointestinal mucosa.
Conclusions
The results suggest that activation of AT2 receptors in-
creases jejunal luminal NO output. This response was not
due to an increase in the expression of the iNOS protein
in the mucosa.
Methods
34 healthy young landrace pigs of both sexes, weighing
21–29 kg were used for the experiments. Biopsies for stud-
ying AT1 and AT2 receptor expression were obtained in a
subset of 11 animals. The animals were fasted over night
with free access to water. The study was approved by the
Ethics Committee of Experiments in Animals, Goteborg
University.
Anesthesia and surgical procedures
Anesthesia was induced by ketamine (Ketalar™, Parke-
Davis, Solna, Sweden) intramuscularly (15 mg per kg
body weight), azaperon (Stresnil™, Jansen-Cilag, Vienna,
Austria) intramuscularly (80 mg) and a bolus of α-chlora-
lose (Kebo Lab, Spanga, Sweden) intravenously (100 mg
per kg body weight). Anesthesia was maintained by intra-
venous infusion of α-chloralose (25 mg per hour and kg
body weight). The lack of response to painful stimuli was
controlled before any surgical procedures. Fentanyl (100–
200  µg) (Fentanyl Alpharma™, Alpharma, Stockholm,
Sweden) was given when needed. The animals were tra-
cheotomized and mechanically ventilated with 30% oxy-
gen in air (Servo 900, Siemens, Stockholm, Sweden) to
normocapnia. Isotonic Rehydrex® solution (2,5% glu-
cose) (Fresenius Kabi, Uppsala, Sweden) was infused at
20 ml per kg body weight during surgery and 10 ml per kg
body weight during the rest of the protocol. Heating blan-
kets kept the core body temperature at 38°C. The right
femoral vein and artery were catheterized for infusions
and monitoring of arterial blood pressure and heart rate
(Datex, Helsinki, Finland). A 7F central venous catheter
(Secalon®T, Ohmeda, Swindon, UK) was inserted into the
left external jugular vein for infusions. A 7F Swan-Ganz
catheter (Baxter Medical AB, Solna, Sweden) was inserted
via the right external jugular vein for measurement of core
body temperature and to determine cardiac output by
thermodilution as the average of triplicate measurements
within a 10% range (Datex, Helsinki, Finland). A midline
laparotomy was performed. An ultrasonic transit-time
flowmetry probe (inner diameter of 16 mm, Transonic
Systems Inc, Ithaca, NY, USA) was positioned around the
portal vein to measure mesenteric blood flow. Small ante-
mesenteric jejunal incisions were made at 80 and 130 cm
distal to the ligament of Treitz, and tonometry catheters
(Tonometrics Inc, Datex-Engstom Div, Helsinki, Finland)
were inserted and advanced 20 cm. Each incision was
tightened by a purse string suture.
NO measurements
Each tonometer was inflated with 5 ml of room air and
left to equilibrate for 15 minutes. The gas was aspirated
into a gas tight syringe and immediately injected into the
sample line of a chemiluminescence analyser (ECO Phys-
ics AG, Dürnten, Switzerland) displaying NO concentra-
tions in parts per billion (ppb) as previously described [9].
Data were collected during the last 15 minutes during
each period of the protocol and represent a mean of the
values obtained from the two tonometry ballons in each
individual.
Western blot iNOS
Antemesenteric jejunal specimens were collected at the in-
sertion sites for tonometry catheters during the surgical
preparation and immediately after the protocol was fin-
ished. The superficial mucosal layer was scraped off and
immediately frozen in liquid nitrogen and subsequently
stored at -70°C. The specimens were sonicated (SonifierBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/2
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450/250, Branson Ultrasonics Co, Danbury, USA) during
2 × 15 min in a PE-buffer (10 mM potassium Phosphate
buffer, pH 6.8, and 1 mM EDTA) containing CHAPS (3-
[(3-cholamidopropyl) dimethyl-ammanio] 1-pro-
panesulfonate), aprotinin (1 µg/ml), leupeptin (10 µg/
ml), pepstatin (10 µg/ml) and Pefablock (1 mg/ml)
(Boeringer Mannheim, Mannheim, Germany). Centrifu-
gation was performed at 10.000 g for 10 min at 4°C. The
supernatant was analysed for protein content by the meth-
od of Bradford [10] and stored at -70°C for further analy-
sis. Samples were diluted in SDS-buffer and heated at
70°C for 10 min before they were loaded on a NuPage 3–
8 % Tris-Acetat gel (NOVEX, San Diego, California, USA).
One lane of each gel was loaded with prestained molecu-
lar weight standards (SeeBlue™, NOVEX, San Diego, CA,
USA). After the electrophoresis the proteins were trans-
ferred to a polyvinyldifluoride membrane (Amersham,
Buckinghamshire, UK) which was incubated with a specif-
ic antibody directed against iNOS (a 21-kDa proteinfrag-
ment corresponding to amino acids 961–1144 of mouse
macrophage NOS) (Transduction Laboratories, Lexing-
ton, Ky, USA). An alkaline phosphatase conjugated goat
anti-rabbit antibody (Santa Cruz, CA, USA) and CDP-Star
(Tropix, Bedford, MA, USA) as a substrate, were used to
identify immunoreactive proteins by chemiluminescense.
Images were captured by a LAS-100 cooled CCD-camera
(Fujifilm, Tokyo, Japan) and semi-quanification was per-
formed using the soft ware Gauge 3.3 (Fujifilm, Tokyo, Ja-
pan). Data were assessed as optical density per microgram
of protein and represent a mean of the values obtained
from tissue sampled from the positions of the two tonom-
etry ballons in each individual.
Western blot AT1 and AT2 receptors
Antemesenteric jejunal specimens (50–80 cm below the
ligament of Treitz) of full wall thickness were collected
immediately after the abdominal incision and snap fro-
zen in liquid nitrogen and subsequently stored at -70°C.
The specimens were homogenized on ice (Polytron, Kine-
matica AG, Switzerland) in buffer A (10% glycerol, 20
mM Tris-HCl pH 7,3, 100 mM NaCl, 2 mM phenylmeth-
ylsulfonyl fluoride, 2 mM EDTA, 2 mM EGTA, 10 mM so-
dium orthovanadate, 10 µg/mL leupeptin, and 10 µg/mL
aprotinin) [11]. Centrifugation was performed at 30.000
g for 30 min at 4°C. The pellet was resuspended in buffer
B (1 % NP-40 (Sigma-Aldrich, Stockholm, Sweden) in
buffer A) and subsequently stirred at 4°C for one hour be-
fore centrifugation at 30.000 g for 30 min at 4°C. The su-
pernatant was analysed for protein content by the method
of Bradford [10] and stored at -70°C for further analysis.
Loading on gels, electrophoresis and blotting procedures
were performed as described above. NuPage 10% Bis-Tris
gels and an electrophoresis running MOPS buffer (Invitro-
gen AB, Sweden) were used. KNRK (for AT2) and PC-12
(for AT1) whole cell lysates serving as positive controls
(Santa Cruz, CA, USA), respectively. Polyvinyldifluoride
membranes were incubated with polyclonal specific anti-
bodies of rabbit origin directed to the AT1 and AT2 recep-
tors, respectively (Santa Cruz, CA, USA). Identification of
immunoreactive proteins and capturing of images were
performed as described above.
rtPCR AT1 and AT2 receptors
Antemesenteric jejunal specimens (50 and 80 cm below
the ligament of Treitz) of full wall thickness were collected
immediately after the abdominal incision, placed in ex-
traction solution RNAStat60 (TEL-TEST Inc, Friendswood,
USA) and snap frozen in liquid nitrogen and stored at -
70°C. The tissue was homogenized on ice (Polytron, Kin-
ematica AG, Switzerland) and total RNA was extracted ac-
cording to the methods supplied by the manufacturer
following phenol-chloroform extraction and ethanol pre-
cipitation. The RNA concentration was quantified by ab-
sorbance measurement at 260 nm and the integrity was
assessed by absorbance measurement at 280 nm. Reverse
transcription was carried out using the SUPERSCRIPT™
First-Strand Synthesis System (Invitrogen AB, Sweden) ac-
cording to the manufacturers instructions. Resulting
cDNA was stored at -20°C until use. Amplification of
cDNA was performed by usage of the PCR Reagent System
(Invitrogen AB, Sweden) in a final volume of 25 µl and ac-
cording to the manufacturers instructions. Primers specif-
ic for human AT1 and AT2 receptors and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) [12] (Table
1) were added at a concentration of 500 nM. The amplifi-
cation was performed using cycles as follows: 94°C for 5
min followed by 35 cycles (AT1 and AT2) or 28 cycles
(GAPDH) at 94°C for 1 min for denaturation, 55°C
(AT1) or 58°C (AT2 and GAPDH) for 1 min for anneal-
ing, 72°C for 1 min for elongation, followed by one cycle
Table 1: rtPCR primer data.
component sense antisense product size
AT1 receptor 5'-GGCCAGTGTTTTTCTTTTGAATTTAGCAC-3' 5'-TGAACAATAGCCAGGTATCGATCAATGC-3' 210 bp
AT2 receptor 5'-GTTCCCCTTGTTTGGTGTAT-3' 5'-CATCTTCAGGACTTGGTCAC-3' 253 bp
GAPDH 5'-CCCATCACCATCTTCCAGGAG-3' 5'-GTTGTCATGGATGACCTTGGCC-3' 284 bp
Sequences of the primers (12) used for PCR analysis on porcine jejunal wall.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/2
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of 72°C for 7 min for final elongation and then samples
were cooled. Cycles were optimized to represent the linear
phase of the PCR reaction. The resulting products were
electrophoresed on a 1,5% agarose-0.5 TBE gel containing
0.5 µg/ml etidium bromide. Visualisation of PCR prod-
ucts was achieved using ultraviolet light and images were
captured by a LAS-100 cooled CCD-camera (Fujifilm, To-
kyo, Japan).
Drugs
CGP 42112A (peptidergic AT2 receptor agonist) (Neosys-
tem, Strasbourg, France) and PD123319 (non-peptidergic
AT2 receptor antagonist) (Research Biochemicals Interna-
tional, Natick, MA, USA) were freshly dissolved in 150
mM sodium chloride solution.
Experimental protocol
All animals were left to stabilise for at least 30 minutes af-
ter surgery. After a baseline period of 45 min the animals
received either saline vehicle (A, n = 5) or CGP 42112A (B,
n = 11). In a third group the AT2-receptor antagonist
PD123319 was administered (0.3 mg kg-1 iv. bolus and
0.03 mg kg-1 h-1 iv. infusion) during baseline and CGP
42112A administered subsequently as in B (C, n = 7).
CGP 42112A was administered at three consecutive infu-
sion rates, each lasting 45 min, starting at 0.01 µg kg-1
min-1 followed by 0.1 µg kg-1 min-1 and 1.0 µg kg-1 min-
1. Hemodynamic variables were recorded continously
with the exception for CO which was determined at the
end of each 45 min period of the protocol.
Statistical analysis
NO output and iNOS protein content were analysed as
calculated individual means. Spearman rank correlation
test was used to test the relation between luminal NO
output and iNOS content in basal conditions. Differences
between pre- and post-treatment iNOS protein expression
were analysed by Wilcoxon signed rank test. Differences
between groups and post- to pre-treatment ratios of iNOS
protein content, as well as relative changes in NO output,
were analysed by the Kruskal-Wallis and the Mann-Whit-
ney U test. Hemodynamic variables were analysed by
ANOVA and the Bonferroni post-hoc test. A p-value less
than 0.05 was considered statistically significant.
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